| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Mixed Poisson Regression Model for Analysis of Patent Data |
0 |
0 |
0 |
290 |
3 |
4 |
8 |
1,746 |
| Are All Patent Examiners Equal? The Impact of Examiner Characteristics |
1 |
1 |
1 |
367 |
7 |
11 |
17 |
2,020 |
| Balancing Incentives: The Tension Between Basic and Applied Research |
0 |
0 |
1 |
419 |
3 |
5 |
8 |
1,891 |
| Characteristics of Demand for Pharmaceutical Products: an Examination of four Cephalosporins |
0 |
0 |
0 |
0 |
4 |
7 |
11 |
2,380 |
| Deals Not Done: Sources of Failure in the Market for Ideas |
0 |
0 |
0 |
31 |
2 |
6 |
8 |
106 |
| Do Patents Matter?: Empirical Evidence after GATT |
0 |
0 |
0 |
297 |
3 |
7 |
7 |
826 |
| Entry and Patenting in the Software Industry |
0 |
0 |
1 |
191 |
6 |
11 |
15 |
655 |
| Faster, Smaller, Cheaper: An Hedonic Price Analysis of PDAs |
0 |
0 |
0 |
101 |
2 |
8 |
9 |
409 |
| Generics and New Goods in Pharmaceutical Price Indexes |
0 |
0 |
0 |
266 |
6 |
8 |
11 |
1,219 |
| Gone But Not Forgotten: Labor Flows, Knowledge Spillovers, and Enduring Social Capital |
0 |
0 |
0 |
269 |
5 |
12 |
18 |
854 |
| Hedonic Analysis of Arthritis Drugs |
0 |
0 |
0 |
163 |
3 |
7 |
9 |
1,024 |
| Industry Effects and Appropriability Measures in the Stock Markets Valuation of R&D and Patents |
0 |
1 |
4 |
391 |
6 |
15 |
20 |
1,182 |
| Is Distance from Innovation a Barrier to the Adoption of Artificial Intelligence? |
0 |
0 |
1 |
19 |
4 |
11 |
19 |
38 |
| Is Distance from Innovation a Barrier to the Adoption of Artificial Intelligence? |
1 |
1 |
5 |
24 |
3 |
7 |
18 |
52 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
0 |
0 |
0 |
157 |
1 |
1 |
3 |
1,637 |
| Is distance from innovation a barrier to the adoption of artificial intelligence |
0 |
3 |
6 |
24 |
8 |
14 |
25 |
51 |
| Is distance from innovation a barrier to the adoption of artificial intelligence |
0 |
0 |
19 |
19 |
2 |
4 |
37 |
37 |
| Market Conditions and Retirement of Physical Capital: Evidence fron Oil Tankers |
0 |
0 |
0 |
44 |
2 |
6 |
9 |
482 |
| Measuring competence?: exploring firm effects in pharmaceutical research |
0 |
1 |
1 |
511 |
2 |
6 |
10 |
1,349 |
| Not Invented Here? Innovation in Company Towns |
0 |
0 |
0 |
83 |
2 |
6 |
9 |
340 |
| Patent Thickets, Licensing and Innovative Performance |
0 |
0 |
1 |
130 |
0 |
2 |
7 |
418 |
| Patent thickets, licensing and innovative performance |
0 |
0 |
0 |
58 |
8 |
8 |
10 |
162 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
0 |
30 |
7 |
9 |
12 |
110 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
0 |
52 |
5 |
12 |
13 |
129 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
0 |
74 |
3 |
7 |
8 |
168 |
| Patents and the Survival of Internet-related IPOs |
0 |
0 |
0 |
84 |
6 |
10 |
14 |
307 |
| Patents and the global diffusion of new drugs |
0 |
0 |
0 |
20 |
4 |
4 |
7 |
95 |
| Patents and the global diffusion of new drugs |
0 |
0 |
0 |
54 |
2 |
5 |
5 |
91 |
| Patents, Thickets, and the Financing of Early-Stage Firms: Evidence from the Software Industry |
0 |
0 |
1 |
104 |
3 |
6 |
10 |
358 |
| Price Indexes for Clinical Trial Research: A Feasibility Study |
0 |
0 |
1 |
32 |
3 |
8 |
19 |
127 |
| Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research |
0 |
0 |
1 |
125 |
2 |
10 |
15 |
379 |
| Public-Private Interaction and the Productivity of Pharmaceutical Research |
0 |
0 |
1 |
189 |
1 |
3 |
9 |
769 |
| Racing or spilling?: the determinants of research productivity in ethical drug discovery |
0 |
0 |
0 |
53 |
2 |
3 |
5 |
192 |
| Racing to invest?: the dynamics of competition in ethical drug discovery |
0 |
0 |
1 |
297 |
5 |
6 |
10 |
608 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery |
0 |
0 |
0 |
1 |
27 |
29 |
34 |
528 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry |
0 |
0 |
2 |
362 |
5 |
18 |
26 |
1,102 |
| Scale, scope and spillovers: the determinants of research productivity in ethical drug discovery |
0 |
0 |
0 |
145 |
2 |
5 |
10 |
336 |
| The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research |
0 |
0 |
2 |
310 |
12 |
16 |
29 |
1,991 |
| The Impact of Artificial Intelligence on Innovation |
2 |
11 |
34 |
429 |
42 |
112 |
287 |
3,516 |
| The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity |
0 |
1 |
1 |
57 |
2 |
4 |
8 |
109 |
| University Research, Industrial R&D, and the Anchor Tenant Hypothesis |
0 |
0 |
1 |
229 |
3 |
8 |
13 |
958 |
| Why are Some Regions More Innovative than Others? The Role of Firm Size Diversity |
0 |
0 |
1 |
101 |
3 |
6 |
12 |
295 |
| Why are some regions more innovative than others? The role of firm size diversity |
0 |
0 |
0 |
87 |
7 |
8 |
9 |
98 |
| Total Working Papers |
4 |
19 |
86 |
6,689 |
228 |
455 |
843 |
31,144 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery |
1 |
2 |
10 |
31 |
8 |
15 |
49 |
116 |
| Access to intellectual property for innovation: Evidence on problems and coping strategies from German firms |
0 |
0 |
1 |
24 |
6 |
8 |
13 |
135 |
| Analysis of Patent Data--A Mixed-Poisson-Regression-Model Approach |
0 |
0 |
0 |
0 |
2 |
4 |
8 |
940 |
| Canada’s Patent Productivity Paradox: Recent Trends and Implications for Future Productivity Growth |
1 |
1 |
7 |
17 |
12 |
20 |
55 |
99 |
| Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins |
0 |
0 |
1 |
411 |
1 |
7 |
16 |
1,179 |
| Deals not done: Sources of failure in the market for ideas |
0 |
0 |
1 |
9 |
5 |
9 |
14 |
90 |
| Diffusion of New Drugs in the Post-TRIPS Era |
0 |
0 |
1 |
54 |
2 |
4 |
6 |
174 |
| Entry and Patenting in the Software Industry |
0 |
0 |
0 |
44 |
6 |
7 |
14 |
261 |
| Faster, smaller, cheaper: an hedonic price analysis of PDAs |
0 |
0 |
0 |
41 |
5 |
8 |
12 |
269 |
| Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy |
0 |
0 |
1 |
27 |
1 |
2 |
7 |
108 |
| Generics and New Goods in Pharmaceutical Price Indexes |
0 |
0 |
1 |
234 |
5 |
9 |
16 |
941 |
| Generics and New Goods in Pharmaceutical Price Indexes: Reply |
0 |
0 |
0 |
35 |
4 |
5 |
6 |
176 |
| Industry Effects and Appropriability Measures in the Stock Market's Valuation of R&D and Patents |
0 |
0 |
3 |
365 |
6 |
10 |
21 |
1,263 |
| Information Technology and Intangible Output: The Impact of IT Investment on Innovation Productivity |
0 |
0 |
4 |
46 |
4 |
9 |
22 |
162 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
0 |
0 |
0 |
29 |
6 |
6 |
10 |
398 |
| Measuring Competence? Exploring Firm Effects in Pharmaceutical Research |
0 |
0 |
2 |
19 |
7 |
15 |
35 |
152 |
| New Pills for Poor People? Empirical Evidence after GATT |
0 |
0 |
0 |
239 |
3 |
7 |
10 |
530 |
| Not Invented Here? Innovation in company towns |
0 |
0 |
0 |
51 |
2 |
6 |
12 |
373 |
| Opportunity costs and entrepreneurial activity |
0 |
0 |
1 |
159 |
3 |
6 |
12 |
482 |
| Patent thickets, licensing and innovative performance |
0 |
0 |
0 |
44 |
1 |
3 |
10 |
167 |
| Patents and the Global Diffusion of New Drugs |
1 |
1 |
1 |
79 |
5 |
9 |
24 |
408 |
| Patents and the survival of Internet-related IPOs |
0 |
0 |
2 |
98 |
3 |
6 |
16 |
417 |
| Patents, Thickets and the Financing of Early‐Stage Firms: Evidence from the Software Industry |
0 |
0 |
3 |
80 |
3 |
5 |
18 |
361 |
| Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs |
0 |
0 |
0 |
0 |
2 |
3 |
9 |
26 |
| Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs |
0 |
0 |
0 |
5 |
7 |
11 |
21 |
54 |
| Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research |
0 |
0 |
0 |
15 |
5 |
9 |
15 |
112 |
| Racing To Invest? The Dynamics of Competition in Ethical Drug Discovery |
0 |
0 |
0 |
12 |
1 |
2 |
11 |
648 |
| Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research |
0 |
2 |
5 |
264 |
6 |
10 |
20 |
660 |
| Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery |
2 |
3 |
8 |
637 |
6 |
10 |
28 |
1,970 |
| The Economics of Reproducibility in Preclinical Research |
0 |
0 |
0 |
10 |
12 |
22 |
33 |
85 |
| The Global Location of Biopharmaceutical Knowledge Activity: New Findings, New Questions |
0 |
0 |
0 |
6 |
4 |
4 |
6 |
56 |
| The Impact of Incremental Innovation in Biopharmaceuticals |
0 |
0 |
1 |
18 |
1 |
4 |
8 |
73 |
| The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems |
0 |
1 |
5 |
218 |
10 |
22 |
39 |
727 |
| Untangling the origins of competitive advantage |
0 |
1 |
4 |
10 |
4 |
5 |
11 |
42 |
| Why are some regions more innovative than others? The role of small firms in the presence of large labs |
0 |
0 |
1 |
81 |
2 |
4 |
14 |
338 |
| Total Journal Articles |
5 |
11 |
63 |
3,412 |
160 |
286 |
621 |
13,992 |
LogEc is hosted by the
Örebro University School of Business.